NASDAQ:XFOR
X4 Pharmaceuticals, Inc
X4 Pharmaceuticals, Inc's revenue grew 150.0% in fiscal 2025 to $6.5M while operating margin rose to −1336.7%. Free cash flow was −$85.6M, −1317.2% of revenue, and the diluted share count rose 531.0%.Summary generated from X4 Pharmaceuticals, Inc's SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$6.5M
Revenue growth+150.0%
Revenue, 5-yr CAGR+16.7%
Gross margin11.4%
Operating margin−1336.7%
Net margin−1218.4%
ROIC−160.2%
Return on equity−76.0%
Debt / equity0.40
Free cash flow−$85.6M
FCF margin−1317.2%
Share count change+531.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 3 | 7 |
| Operating income | −85 | −88 | −108 | −36 | −87 |
| Net income | −89 | −94 | −101 | −37 | −79 |
| Free cash flow | −72 | −77 | −97 | −131 | −86 |
Recent filings
- 8-KEntry into a material agreement
Oct 8, 2026 - 4Insider transaction report
Oct 5, 2026 - 8-KOther events
Sep 9, 2026 - 8-KOther events
Sep 8, 2026 - 4Insider transaction report
Aug 13, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KDirector or officer change
Jul 1, 2026 - 8-K/AAmended director or officer change
May 13, 2026